Vericel Corp
StreetZero Signal 57
About Vericel Corp
Vericel Corporation develops autologous stem cell therapies for patients with severe burns and cartilage defects. The company is headquartered in Cambridge, Massachusetts and is publicly traded on NASDAQ under VCEL. It offers products such as MACI for cartilage repair and Epicel for burn care.
LATEST FUNDINGRule 144
$157K
Announced 2026-11-05
TOTAL RAISED$157.3M
IN THE NEWS
- 🔗 Vericel Corporation - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 Vericel Corp
- 🔗 Bank of New York Mellon Corp Makes New Investment in Vericel Corporation $VCEL
- 🔗 Vericel details MACI and burn-care growth strategy | VCEL Annual Report (10-K)
- 🔗 VCEL SEC Filings, Mar-May 2026 - Vericel Corp Filing Archive
EMPLOYEES529
FOUNDED1989
HQCambridge, MA, United States
Industry
Public Equity (NASDAQ)
Tags
PublicBiotechnologyRegenerative Medicine
Key highlights
- Raised $74.8M in post-IPO equity in 2018
- Public company on NASDAQ:VCEL with market cap over $2B
- Focus on autologous cell therapies for burns and cartilage
- Reported revenue guidance of $330M-$340M for FY2026
- Generated positive free cash flow in recent quarters
Ask StreetZero about Vericel Corp
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account